These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Determination of bioequivalence of psychotropic drugs and concerns involving product interchange. Barone JA; Byerly WG J Clin Psychiatry; 1986 Sep; 47 Suppl():28-32. PubMed ID: 2875067 [TBL] [Abstract][Full Text] [Related]
3. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300 [TBL] [Abstract][Full Text] [Related]
4. Assessing individual bioequivalence with high-order cross-over designs: a unified procedure. Hsuan FC; Reeve R Stat Med; 2003 Sep; 22(18):2847-60. PubMed ID: 12953284 [TBL] [Abstract][Full Text] [Related]
5. In vitro bioequivalence testing. Chow SC; Shao J; Wang H Stat Med; 2003 Jan; 22(1):55-68. PubMed ID: 12486751 [TBL] [Abstract][Full Text] [Related]
6. Generic substitution: issues for problematic drugs. Henderson JD; Esham RH South Med J; 2001 Jan; 94(1):16-21. PubMed ID: 11213935 [TBL] [Abstract][Full Text] [Related]
7. Some thoughts on individual bioequivalence. Liu J; Chow SC J Biopharm Stat; 1997 Mar; 7(1):41-8. PubMed ID: 9056587 [No Abstract] [Full Text] [Related]
8. Assessing individual bioequivalence using the structural equation model. Carrasco JL; Jover L Stat Med; 2003 Mar; 22(6):901-12. PubMed ID: 12627408 [TBL] [Abstract][Full Text] [Related]
9. United States Food and Drug Administration requirements for approval of generic drug products. Meyer MC J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846 [TBL] [Abstract][Full Text] [Related]
10. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs. Quiroz J; Ting N; Wei GC; Burdick RK Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892 [TBL] [Abstract][Full Text] [Related]
11. Bioavailability and bioequivalence trials: statistics & pharmacokinetic principles. Rajaram L; Roy SK; Skerjanec A Stud Health Technol Inform; 2004; 103():159-79. PubMed ID: 15747918 [TBL] [Abstract][Full Text] [Related]
14. FDA's Center for Biologics Evaluation and Research comments on the Report of the expert panel. Quinnan GV Public Health Rep; 1991; 106(1):31. PubMed ID: 1842893 [No Abstract] [Full Text] [Related]
15. The FDA's restrictions against prescription drug advertising: more hindrance than help. Lorman AJ Healthspan; 1991 Nov; 8(10):3-7. PubMed ID: 10114942 [No Abstract] [Full Text] [Related]
17. Not enough warning. GAO report finds FDA's medical device monitoring lacking. Hensley S Mod Healthc; 1997 Mar; 27(10):102, 104. PubMed ID: 10165267 [No Abstract] [Full Text] [Related]
18. Requirements for submission of bioequivalence data; final rule. Final rule. Food and Drug Administration, HHS Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107 [TBL] [Abstract][Full Text] [Related]
19. Bioequivalence/bioavailability retention samples. Ransom C Qual Assur; 1993; 2(1-2):42-3. PubMed ID: 8156218 [No Abstract] [Full Text] [Related]